Akums Drugs and Pharmaceuticals Limited — PPTs, 08-08-2025: Investor Presentation

Here is the financial summary:

**Financial Highlights:**

* Q1 FY26 consolidated total income reached ₹1,051 Cr (+2.4% YoY). Adjusted EBITDA stood at ₹156 Cr (14.8% margin, +208 bps YoY), with Adjusted PAT at ₹65 Cr (6.2% margin, +57 bps YoY).

* Cash surplus surged to ₹1,518 Cr (from ₹566 Cr in FY25) following a €100 Mn advance for a European CDMO contract.

* CDMO segment accounts for 79.4% of revenue, showing improved gross margins driven by a focus on niche products.

**Strategic Initiatives & Growth Drivers:**

* Achieved 1,000 DCGI approvals, with 27 secured in Q1 FY26.

* Received first EU dossier approval (Rivaroxaban) and filed first Dapagliflozin combination dossier in Switzerland.

* EU contract commercial supplies are on track to commence by April 2027. Strong liquidity supports organic and inorganic growth.

* Implemented Zero Liquid Discharge (ZLD) across 5 plants.

**Business Developments:**

* Secured a €100 Mn advance payment for the European CDMO contract.

* Received Brazil ANVISA approval for Plant 3 and Russia GMP for Plant 4.

* Strengthened senior leadership teams across IT, Finance, and Strategy.

**Market Position & Competitive Advantage:**

* The company aims to be a leading global CDMO, leveraging its robust R&D pipeline for long-term growth.

* Despite overall market volume growth being muted (<0.5%) and continued weakness in API pricing, the company remains well-positioned.

**Investor Implications:**

* The substantial cash surplus and expanding pipeline of approvals indicate positive growth potential.

* Focus on niche products and CDMO leadership could enhance future profitability.

* However, the ongoing softness in market volumes and API prices presents an execution risk to monitor.